Outcomes for autologous stem cell transplant in first remission for PTCL
| Study . | N (enrolled) . | N by PTCL subtype . | N (TXP) . | Median age (years; range) . | EFS/PFS (years) . | OS (years) . |
|---|---|---|---|---|---|---|
| d’Amore et al25 | 160 | PTCL-NOS—62 | 115 (72%) | 57 (22-67) | 44% (5) | 51% (5) |
| AITL—30 | ||||||
| ALCL—31 | ||||||
| Reimer et al15 | 83 | PTCL-NOS—32 | 55 (66%) | 47 (30-65) | 36% (3) | 48% (3) |
| AITL—27 | ||||||
| ALCL—12 | ||||||
| Corradini et al56 | 62 | PTCL-NOS—28* | 46 (74%) | 43 (20-60) | 30 (12) | 34 (12) |
| AITL—10 | ||||||
| ALCL—19† | ||||||
| Mehta et al13 | 65‡ | PTCL-NOS—32 | 39 (60%) | 58 (22-75) | 38% (4) | 52% (4) |
| AITL—21 | ||||||
| ALCL—12 |
| Study . | N (enrolled) . | N by PTCL subtype . | N (TXP) . | Median age (years; range) . | EFS/PFS (years) . | OS (years) . |
|---|---|---|---|---|---|---|
| d’Amore et al25 | 160 | PTCL-NOS—62 | 115 (72%) | 57 (22-67) | 44% (5) | 51% (5) |
| AITL—30 | ||||||
| ALCL—31 | ||||||
| Reimer et al15 | 83 | PTCL-NOS—32 | 55 (66%) | 47 (30-65) | 36% (3) | 48% (3) |
| AITL—27 | ||||||
| ALCL—12 | ||||||
| Corradini et al56 | 62 | PTCL-NOS—28* | 46 (74%) | 43 (20-60) | 30 (12) | 34 (12) |
| AITL—10 | ||||||
| ALCL—19† | ||||||
| Mehta et al13 | 65‡ | PTCL-NOS—32 | 39 (60%) | 58 (22-75) | 38% (4) | 52% (4) |
| AITL—21 | ||||||
| ALCL—12 |